Pfizer (NYSE:PFE) was downgraded by equities researchers at Goldman Sachs Group Inc. from a “conviction-buy” rating to a “buy” rating in a research report issued on Tuesday, TheFlyOnTheWall.com reports.
A number of other analysts have also recently weighed in on PFE. Analysts at TheStreet reiterated a “buy” rating on shares of Pfizer in a research note to investors on Friday. Separately, analysts at Thomson Reuters/Verus upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note to investors on Monday, November 25th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Pfizer currently has an average rating of “Buy” and a consensus target price of $31.78.
Pfizer (NYSE:PFE) opened at 31.83 on Tuesday. Pfizer has a 1-year low of $24.63 and a 1-year high of $32.50. The stock has a 50-day moving average of $31.15 and a 200-day moving average of $29.26. The company has a market cap of $206.3 billion and a P/E ratio of 8.79.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The company reported $0.58 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.56 by $0.02. The company had revenue of $12.64 billion for the quarter, compared to the consensus estimate of $12.69 billion. During the same quarter last year, the company posted $0.53 earnings per share. Pfizer’s revenue was down 2.4% compared to the same quarter last year. On average, analysts predict that Pfizer will post $2.18 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, December 3rd. Investors of record on Friday, November 8th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend is Wednesday, November 6th.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.